The Big Maple Heads to Boston
As the hours wound down on MLB’s collective bargaining agreement, the Red Sox took one last flier, signing left-handed pitcher James Paxton to a one-year deal worth $10 million, with a two-year, $26 million club option.
Never a bastion of durability — he’s never thrown enough innings in a major league season to qualify for the ERA title — Paxton’s had a particularly rough couple of seasons. In 2020, he underwent surgery to remove a peridiscal cyst, a type of spinal lesion, but last year’s late July start gave him enough time to be ready for the season. Unfortunately, when the season actually did get underway, he was missing about 3 mph from his fastball and suffered from significant soreness in his elbow. That soreness was diagnosed as a flexor strain, but there was no ligament damage found at the time. The New York Yankees had initially been hopeful that he’d recover to at least make a postseason appearance, but further setbacks prevented him from returning.
After signing with his old team, the Seattle Mariners, the 2021 season didn’t go any better. It only took five batters for an injury to knock Paxton out for the year, requiring Tommy John surgery. This can’t be described as anything but a brutal setback for a player who, from 2016-19, had finally settled into a pattern of being mostly healthy if used carefully. Read the rest of this entry »